kynurenine has been researched along with Pancreatitis in 4 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kynurenine monooxygenase (KMO) blockade protects against multiple organ failure caused by acute pancreatitis (AP), but the link between KMO and systemic inflammation has eluded discovery until now." | 8.31 | Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis. ( Baillie, JK; Baily, J; Binnie, M; Bochkina, NA; Garden, OJ; Hayes, AJ; Homer, NZM; Howie, SEM; Iredale, JP; Just, G; Liddle, J; McGuire, K; Mole, DJ; Murray, TBJ; Neyton, LPA; O'Kelly, J; Skouras, C; Uings, I; Webster, SP; Zheng, X, 2023) |
| "A series of potent, competitive and highly selective kynurenine monooxygenase inhibitors have been discovered via a substrate-based approach for the treatment of acute pancreatitis." | 7.85 | The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis. ( Beaufils, B; Binnie, M; Bouillot, A; Denis, AA; Hann, MM; Haslam, CP; Holmes, DS; Hutchinson, JP; Kranz, M; Liddle, J; McBride, A; Mirguet, O; Mole, DJ; Mowat, CG; Pal, S; Rowland, P; Trottet, L; Uings, IJ; Walker, AL; Webster, SP, 2017) |
| "These results support the concept that mesenteric lymph-borne kynurenines may contribute to pancreatitis-associated MOF." | 7.74 | Tryptophan catabolites in mesenteric lymph may contribute to pancreatitis-associated organ failure. ( Collett, G; Deitch, EA; Diamond, T; Garden, OJ; Kylanpaa, L; McFerran, NV; Mole, DJ; O'Neill, C; Repo, H, 2008) |
| "GSK3335065 is an inhibitor of kynurenine monooxygenase (KMO) being developed for the treatment of acute pancreatitis." | 5.51 | Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers. ( Bergeal, M; Crause, M; Cui, Y; Dimelow, R; Fernando, D; Gorey, C; Guiney, W; Krug, AW; Muya, C; Parker, C; Robertson, N; Soleman, S; Uings, I; Vlasakakis, G; Walsh, S; Wright, W; Zhu, X, 2022) |
| "Kynurenine monooxygenase (KMO) blockade protects against multiple organ failure caused by acute pancreatitis (AP), but the link between KMO and systemic inflammation has eluded discovery until now." | 4.31 | Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis. ( Baillie, JK; Baily, J; Binnie, M; Bochkina, NA; Garden, OJ; Hayes, AJ; Homer, NZM; Howie, SEM; Iredale, JP; Just, G; Liddle, J; McGuire, K; Mole, DJ; Murray, TBJ; Neyton, LPA; O'Kelly, J; Skouras, C; Uings, I; Webster, SP; Zheng, X, 2023) |
| "A series of potent, competitive and highly selective kynurenine monooxygenase inhibitors have been discovered via a substrate-based approach for the treatment of acute pancreatitis." | 3.85 | The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis. ( Beaufils, B; Binnie, M; Bouillot, A; Denis, AA; Hann, MM; Haslam, CP; Holmes, DS; Hutchinson, JP; Kranz, M; Liddle, J; McBride, A; Mirguet, O; Mole, DJ; Mowat, CG; Pal, S; Rowland, P; Trottet, L; Uings, IJ; Walker, AL; Webster, SP, 2017) |
| "These results support the concept that mesenteric lymph-borne kynurenines may contribute to pancreatitis-associated MOF." | 3.74 | Tryptophan catabolites in mesenteric lymph may contribute to pancreatitis-associated organ failure. ( Collett, G; Deitch, EA; Diamond, T; Garden, OJ; Kylanpaa, L; McFerran, NV; Mole, DJ; O'Neill, C; Repo, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayes, AJ | 1 |
| Zheng, X | 1 |
| O'Kelly, J | 1 |
| Neyton, LPA | 1 |
| Bochkina, NA | 1 |
| Uings, I | 2 |
| Liddle, J | 2 |
| Baillie, JK | 1 |
| Just, G | 1 |
| Binnie, M | 2 |
| Homer, NZM | 1 |
| Murray, TBJ | 1 |
| Baily, J | 1 |
| McGuire, K | 1 |
| Skouras, C | 1 |
| Garden, OJ | 2 |
| Webster, SP | 2 |
| Iredale, JP | 1 |
| Howie, SEM | 1 |
| Mole, DJ | 3 |
| Fernando, D | 1 |
| Dimelow, R | 1 |
| Gorey, C | 1 |
| Zhu, X | 1 |
| Muya, C | 1 |
| Parker, C | 1 |
| Wright, W | 1 |
| Soleman, S | 1 |
| Walsh, S | 1 |
| Crause, M | 1 |
| Vlasakakis, G | 1 |
| Guiney, W | 1 |
| Robertson, N | 1 |
| Bergeal, M | 1 |
| Cui, Y | 1 |
| Krug, AW | 1 |
| Beaufils, B | 1 |
| Bouillot, A | 1 |
| Denis, AA | 1 |
| Hann, MM | 1 |
| Haslam, CP | 1 |
| Holmes, DS | 1 |
| Hutchinson, JP | 1 |
| Kranz, M | 1 |
| McBride, A | 1 |
| Mirguet, O | 1 |
| Mowat, CG | 1 |
| Pal, S | 1 |
| Rowland, P | 1 |
| Trottet, L | 1 |
| Uings, IJ | 1 |
| Walker, AL | 1 |
| McFerran, NV | 1 |
| Collett, G | 1 |
| O'Neill, C | 1 |
| Diamond, T | 1 |
| Kylanpaa, L | 1 |
| Repo, H | 1 |
| Deitch, EA | 1 |
1 trial available for kynurenine and Pancreatitis
| Article | Year |
|---|---|
Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers.
Topics: Acute Disease; Double-Blind Method; Healthy Volunteers; Humans; Kynurenine; Male; Mixed Function Oxy | 2022 |
3 other studies available for kynurenine and Pancreatitis
| Article | Year |
|---|---|
Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis.
Topics: Acute Disease; Animals; Critical Illness; Inflammation; Kynurenine; Kynurenine 3-Monooxygenase; Mice | 2023 |
The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis.
Topics: Animals; Benzoxazoles; Drug Discovery; Enzyme Inhibitors; HEK293 Cells; Humans; Indazoles; Kynurenin | 2017 |
Tryptophan catabolites in mesenteric lymph may contribute to pancreatitis-associated organ failure.
Topics: Acute Disease; Animals; Kynurenine; Ligation; Lymph; Male; Mesentery; Multiple Organ Failure; Neutro | 2008 |